A finger prick blood test shows promise in the ability to detect Alzheimer’s disease, according to research reported for the first time today at the Alzheimer’s Association International Conference (AAIC) 2023.
The blood test was more than 80% accurate in identifying Alzheimer’s-related changes - significantly better than doctors in the study who did not have access to the test.
"These findings are timely and important with the approvals of Alzheimer’s treatments targeting amyloid-beta, where confirmation of amyloid buildup and biomarker monitoring are required to receive treatment"Advances in technology and practice reported for the first time at the conference demonstrate the simplicity, transportability and diagnostic value of blood-based biomarkers for Alzheimer’s, including the future potential for at-home testing by a patient or a family member.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze